Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment · Journal article
Pharmaceutics · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a feasibility and proof-of-concept study in engineered orthotopic prostate cancer xenografts demonstrating that combined external beam radiotherapy and 177Lu-PSMA-617 produces greater tumor suppression than single-agent therapy. The work establishes a tracking model for preclinical research but provides no efficacy or safety data applicable to patients.
Uncontrolled preclinical xenograft study. PSMA-expressing C4-2 prostate cancer cells with stably integrated triple-reporter genes (mRFP, luc2, HSV1-tk); orthotopic and subcutaneous xenografts in mice.. Intervention: Combined external beam radiotherapy (2 Gy single dose) and 177Lu-PSMA-617 (14.8 MBq), or 177Lu-PSMA-617 alone, or X-ray alone.. Compared with: Control groups (untreated); comparison between single-treatment and combined-treatment arms but without formal statistical analysis.. Not stated..
C4-2 3R cells stably expressed triple reporter genes with detectable orthotopic bioluminescence within one week, persisting for at least five weeks X-ray exposure induced redistribution of PSMA to the cell membrane without increasing total PSMA levels Combined EBRT and 177Lu-PSMA-617 treatment produced higher 18F-PSMA-1007 uptake and stronger tumor suppression with minimal residual tumor mass compared to single-treatment or control groups
No pharmacokinetics, dosimetry, or safety data reported; no comparison to established preclinical prostate cancer models.
This preclinical study does not support clinical decision-making or change in practice. It provides preliminary evidence that X-ray-induced PSMA redistribution may enhance targeted radioligand therapy efficacy in engineered tumor models and warrants further investigation in more rigorous preclinical and, eventually, clinical studies.
Early-phase preclinical study in engineered xenograft models evaluating a novel combination approach; no clinical efficacy data, surrogate endpoints only, and single-arm treatment groups without formal statistical comparison.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical study does not support clinical decision-making or change in practice. It provides preliminary evidence that X-ray-induced PSMA redistribution may enhance targeted radioligand therapy efficacy in engineered tumor models and warrants further investigation in more rigorous preclinical and, eventually, clinical studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Because human prostate cancer (PCa) typically exhibits slow tumor growth, establishing reliable PCa tumor models is often time-consuming and unpredictable, thereby limiting the efficiency of preclinical theranostic research. To overcome this limitation, this study employed a non-viral PiggyBac transposon system to introduce triple-reporter genes into PSMA-expressing C4-2 cells, generating orthotopic and subcutaneous xenograft models that allow noninvasive, real-time monitoring of PCa progression and treatment response. Methods: Reporter-engineered C4-2 3R cells were generated by co-transfecting constructs encoding the reporter cassette and PB transposase, followed by enrichment through fluorescence microscopy and fluorescence-activated cell sorting (FACS) and implantation orthotopically or subcutaneously into mice. Tumor growth and treatment response to a single 2 Gy X-ray dose followed by 14.8 MBq of 177Lu-PSMA-617, or to each monotherapy, were monitored weekly using an IVIS imaging system. Imaging findings were validated by tumor dissection and hematoxylin and eosin (H&E) staining, while PSMA expression was assessed by Western blotting and 18F-PSMA-1007 PET/CT. Results: C4-2 3R cells stably expressed the triple reporter genes (mRFP, luc2, and HSV1-tk), generating detectable orthotopic bioluminescence within one week and persisting for at least five weeks. In contrast, subcutaneous implantation generated only transient luc2 signals with no tumor formation. X-ray exposure did not increase total PSMA levels but induced the redistribution of PSMA to the cell membrane. Combined external beam radiotherapy (EBRT) and 177Lu-PSMA-617 treatment produced higher 18F-PSMA-1007 uptake and stronger tumor suppression, with minimal residual tumor mass, as compared to single-treatment or control groups. Conclusions: This preliminary investigation suggests that the C4-2 3R model provides a practical and trackable tool for investigating slow-growing PCa tumors and evaluating PSMA-targeted therapies, either alone or in combination with EBRT.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.